|
| . |
|
. |
|
 |
|
|
| specificities & advantages |
human PBMCs |
|
| | > | | | reproduction of pro-inflammatory conditions |
| | > | | | investigation of the effects of active biological agents on inflammation (anti-inflammatory effects) |
| | > | | | identification & expression of the biomarkers (cytokines, chemokines…) involved |
| | > | | | possibility to analyse the immunomodulatory response of an active biological agent directly on release mediators from human PBMCs as early as the preclinical development phase |
|
|
| |
|
|
|
